PRESS RELEASE For immediate release Devonian Health Group Announces Closing of a Private Placement and the Grant of Stock Options. Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, December 30, 2020 –...
Press Releases
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS. QUEBEC City, October 9, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage...
Devonian announces correction to press release issued July 28, 2020
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES CORRECTION TO PRESS RELEASE ISSUED JULY 28, 2020. QUEBEC, July 30, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation,...
Devonian announces the issuance of units in settlement of interests owed to a debenture holder and stock option grants
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO A DEBENTURE HOLDER AND STOCK OPTION GRANTS. QUEBEC, July 28, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a...
Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering use of Thykamine™ for the treatment of Ulcerative Colitis
PRESS RELEASE For immediate release Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering use of Thykamine™ for the treatment of Ulcerative Colitis. QUEBEC, June 15, 2020 – Devonian Health Group Inc. (“Devonian” or the...
Devonian Health Group announces completion of Enrollment in its Phase 2 Clinical Trial of Thykamine™ for the Treatment of mild-to-moderate Atopic Dermatitis in adult population
PRESS RELEASE For immediate release Devonian Health Group announces completion of Enrollment in its Phase 2 Clinical Trial of Thykamine™ for the Treatment of mild-to-moderate Atopic Dermatitis in adult population. Last-patient-last-visit took place on June 3rd,...
Devonian Health Group Announces Change to its Board of Directors
PRESS RELEASE For immediate release Devonian Health Group Announces Change to its Board of Directors. QUEBEC, June 5, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical pharmaceutical corporation, focused...
Devonian Health Group Announces an Exclusive Strategic Alliance with CannTx Life Sciences for the development of Cannabinoid-based Pharmaceutical Drugs
PRESS RELEASE For immediate release Devonian Health Group Announces an Exclusive Strategic Alliance with CannTx Life Sciences for the development of Cannabinoid-based Pharmaceutical Drugs. Combination of Devonian’s Botanical Drug expertise with CannTx Life...
Devonian Health Group Announces the nomination of Dr André P. Boulet to the American Botanical Drug Association
PRESS RELEASE For immediate release Devonian Health Group Announces the nomination of Dr André P. Boulet to the American Botanical Drug Association. Dr Boulet to represent Canada within the organization QUEBEC, May 21st, 2020 – Devonian Health Group Inc....
Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing
PRESS RELEASE For immediate release Devonian Health Group Announces the Closing of $1,805,000 Non-Brokered Financing. QUÉBEC CITY, May 4, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD), a clinical stage botanical pharmaceutical...